IRP Study Provides Insight into Cancer Treatment’s Skin-Thickening Side Effects
Scientists have long dreamt of leveraging information about our genes to personalize medical treatment. However, in working towards that effort, they have increasingly discovered the importance not just of what genetic variants are present in a person’s DNA, but how active each of those genes is. Now, new IRP research suggests the possibility of using that information to personalize medical treatment for patients who experience serious skin problems after receiving a transplant of the bone marrow’s blood-producing stem cells.
Research Suggests Hormonal Exposures In-Utero Influence Mental Health
Over the past few decades, broad stereotypes about how men and women behave have given way to a more nuanced understanding of the many factors that contribute to sex differences. While culture and environment undoubtedly play a huge role, it’s becoming increasingly clear that biological influences shape male and female brains differently starting at the very beginning of life. Recent IRP research sheds additional light on this age-old question by revealing that women exposed to higher levels of certain hormones in-utero had emotional responses to the stresses of the COVID-19 pandemic that more closely matched those of men.
IRP Research Explores the Health Effects of Specific Dietary Components
When Hippocrates said, “Let food by thy medicine and medicine thy food,” he was on to something. That’s why National Nutrition Month, celebrated every March, calls attention to the important link between health and diet. To commemorate Nutrition Month this year, we spoke with IRP senior investigator Rashmi Sinha, Ph.D., about her efforts to tease out not only which foods help or harm out bodies, but why they do so.
Determining the health effects of different foods has long been a holy grail in research, but with so many variables, our knowledge remains vague at best. Some foods — processed meats, certain fats, sugar — clearly have negative effects when eaten in large amounts, while others like green vegetables and legumes are helpful. Unfortunately, there are a lot of unknowns in between.
IRP’s Susan Harbison Unravels the Genetics of Sleep Disorders
Comedian George Carlin used to call sleep “a bizarre activity.” In his act, he observed, “For the next several hours, while the sun is gone, I’m going to become unconscious, temporarily losing command over everything I know and understand. When the sun comes up, I’ll resume my life.”
Every year on March 15, the celebration of World Sleep Day reminds us that sleep remains a baffling biological mystery. What happens when we sleep, why we need it, and why it varies so much between individuals are still unclear despite the best efforts of many scientists. That enduring enigma is what has driven IRP senior investigator Susan Harbison, Ph.D., to investigate the biological basis and genetics of sleep.
Treatment Could Benefit Patients With a Variety of Illnesses
Our blood is a miraculous mix of cells and critical fluids that keep our organs running and fight off dangerous infections. Of course, for blood to do its job, it has to stay in our veins and arteries, which is easier said than done for people with certain illnesses. Fortunately, a recent IRP study has demonstrated the promise of a potential new treatment for people with dangerously leaky blood vessels.
Several life-threatening conditions, including Ebola and sepsis due to an uncontrolled infection, cause the fluid component of blood to leak out of blood vessels. IRP senior investigator Kirk Druey, M.D., however, came to study the phenomenon through a very rare ailment called Clarkson disease, which causes patients to periodically experience ‘flares’ or ‘episodes’ when their veins and arteries suddenly and inexplicably start leaking.
Event Highlights Efforts of Early-Career Researchers
The IRP’s reputation as a leader in biomedical research attracts scientists in all stages of their careers and from all corners of the U.S. and the world. Once a year, the motley collection of graduate students who are completing their Ph.D. research in NIH labs gets to tout its scientific accomplishments at NIH’s Graduate Student Research Symposium, which took place this year on February 15.
During the event’s two poster sessions, more than 120 IRP graduate students presented the results of their research so far, from the development of better ways to grow retina-like collections of cells in the lab to insights into how the brain regulates feelings of hunger. Read on for a brief look at a few of the IRP’s brilliant budding scientists and the discoveries they showed off at the event.
Patients With Rare Metabolic Conditions Yield Insights Into Common Ailments
Young doctors are taught the adage, “When you hear hoofbeats, think horses, not zebras.” Just as you would not expect to find a zebra in your barn, when making a diagnosis, you generally don’t expect to find an unusual disease. However, just as there are still zebras in the world, there are also rare diseases. On Rare Disease Day, celebrated on the last day of February each year, we call attention to the 300 million people affected by them.
Defined as conditions that affect fewer than 1 in 2,000 people, rare diseases pose both challenges and opportunities to medical research. Because they are so uncommon, diagnosis can take years, and treatments may be difficult to obtain or may not yet exist. However, for IRP Lasker Clinical Research Scholar Rebecca J. Brown, M.D., M.H.Sc., the study of several rare metabolic diseases may shed light on the causes of one of the most common diseases in the U.S.
Allana T. Forde Unpacks Racial Disparities in Heart Health
Discrimination comes in many forms, and people experience it and cope with it in different ways. The accumulation of stress arising from discrimination can lead to wear and tear on the body in a process called ‘weathering’, which ultimately harms cardiovascular health. This is one of the key reasons Black Americans have a higher rate of cardiovascular disease than all other racial and ethnic groups in the U.S. and are much more likely to die from cardiovascular conditions than other racial and ethnic groups.
NIH Stadtman Investigator Allana T. Forde, Ph.D., M.P.H., hopes to reduce these startling health disparities by examining how psychosocial stressors, including discrimination, affect the cardiovascular health of subgroups of the Black population, including Afro-Caribbean, Afro-Latino, and African American individuals. She also endeavors to identify the protective and adaptive factors that impact the relationship between discrimination and cardiovascular health. In honor of American Heart Month, I spoke with Dr. Forde about her research on discrimination and cardiovascular health in Black Americans, as well as how her research might improve cardiovascular health and inform cardiovascular disease prevention strategies.
Dr. Dilys Parry died peacefully in her sleep in the early morning of February 2, 2024, after a long illness. For 30 years, Dr. Parry was a staff clinician and principal investigator in the Division of Cancer Epidemiology and Genetics (DCEG) at NIH's National Cancer Institute (NCI). Following her retirement from federal service in 2007 she continued to engage with her colleagues on projects as a special volunteer.
Dr. Parry’s medical genetics research focused primarily on genetic and clinical studies of neurofibromatosis 2 (NF2) and chordoma, a rare bone tumor derived from the notochord, and adult brain tumors. She was deeply committed to educating patients about the natural history of these diseases and helping them and at-risk relatives receive genetic testing or other types of screening to aid in early detection and treatment. Her research helped to identify susceptibility genes for and delineate the spectrum of clinical manifestations associated with NF2 and chordoma. She also elucidated correlations between the specific types of variants in the gene NF2 and clinical findings. Much of the momentum that exists in chordoma research traces back to Dr. Parry’s early interest in the disease.
Case Studies Highlight New Way to Treat Common Side Effect
New medical treatments nearly always come packaged with new side effects. CAR-T cell therapy, a game-changing ‘immunotherapy’ for cancer, is no exception. However, a set of case studies reported by IRP researchers could help physicians better contend with one of the therapy’s most worrisome complications.
CAR-T cell therapy involves collecting immune cells called T cells from a patient's blood, genetically modifying them to turn them into cancer killers, growing millions of the modified cells in the lab, and then returning the cancer-seeking missiles to the patient’s body. As promising as the approach is for eliminating cancer, the first CAR-T cell therapy was approved by the U.S. Food and Drug Administration (FDA) only a bit more than six years ago, so clinicians are still figuring out the best ways to manage its less desirable effects.
This page was last updated on Friday, January 14, 2022
